Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $85 Price Target

Benzinga · 10/15 15:10
Cantor Fitzgerald analyst Kristen Kluska reiterates Disc Medicine (NASDAQ:IRON) with a Overweight and maintains $85 price target.